UBS Group Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by investment analysts at UBS Group from $1,090.00 to $1,099.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would suggest a potential upside of 21.95% from the company’s previous close.

A number of other brokerages also recently weighed in on REGN. Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $901.19 on Wednesday. The company has a market capitalization of $98.91 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $998.33. The firm’s 50 day moving average is $955.19 and its 200-day moving average is $890.52. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $10.96 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 38.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 over the last three months. Insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. FMR LLC raised its position in Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the last quarter. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after purchasing an additional 39,780 shares during the last quarter. Capital World Investors raised its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the last quarter. Putnam Investments LLC grew its holdings in Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the period. Finally, Northern Trust Corp grew its holdings in Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after acquiring an additional 34,326 shares during the period. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.